Another phase 2b placebo-controlled trial, which investigated an oral GLP-1 Ra, danuglipron, demonstrated improved HbA1c, basal glycemia, and BWR in patients with T2DM in the active group [46]. This evidence concerns the gene GCG and type 2 diabetes mellitus.